Share This Page
Drug Price Trends for NDC 83324-0155
✉ Email this page to a colleague
Average Pharmacy Cost for 83324-0155
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QC ADULT TUSSIN CF LIQUID | 83324-0155-04 | 0.01953 | ML | 2025-12-17 |
| QC ADULT TUSSIN CF LIQUID | 83324-0155-04 | 0.01944 | ML | 2025-11-19 |
| QC ADULT TUSSIN CF LIQUID | 83324-0155-04 | 0.01933 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 83324-0155
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 83324-0155
Introduction
The drug identified by National Drug Code (NDC) 83324-0155 pertains to a specific pharmaceutical product whose market dynamics and pricing trends are essential for stakeholders, including pharmaceutical manufacturers, healthcare providers, payers, and investors. Analyzing its current market positioning, competitive landscape, demand-supply factors, and pricing trajectory offers valuable insights for strategic decision-making within the pharmaceutical landscape.
Product Overview
While specific product details for NDC 83324-0155 require confirmation from the FDA's NDC Directory, the NDC code pattern indicates it is assigned to a branded or generic drug listed for outpatient use. Typically, the first segment (83324) corresponds to a manufacturer or labeler, while the subsequent segments detail the product's strength, form, and package size (0155).
Assuming this NDC matches a targeted therapy—for example, a biologic or specialty drug—the market dynamics differ significantly based on therapeutic area, manufacturer exclusivity, and regulatory status.
Market Landscape and Competitive Positioning
1. Therapeutic Area & Demand Drivers
If NDC 83324-0155 relates to a specialty or biologic medication—for example, in oncology, autoimmune disorders, or rare diseases—market demand is primarily driven by:
- Rising prevalence of chronic conditions
- Unmet medical needs
- Advances in personalized medicine
- Expanding indications approved by regulatory agencies
In contrast, traditional small-molecule drugs may face generic competition, influencing price and market share.
2. Regulatory Status and Patent Life
The exclusivity period assigned via patent rights or biologics' reference product exclusivity significantly impacts pricing dynamics. As patents expire or biosimilar pathways become available, price erosion is inevitable. If the product in question is still under patent, it is positioned for premium pricing with a protected market share.
3. Market Penetration and Adoption
Key factors influencing pharmaceutical uptake include:
- Pricing and reimbursement policies: Payers' coverage decisions directly shape market access.
- Physician prescribing patterns: Influenced by clinical guidelines, efficacy, safety profiles.
- Patient preference and adherence: Availability of administration routes, side effects, and cost impact adherence rates.
Historical Pricing Trends and Benchmarking
Without exclusive public data on NDC 83324-0155, analogs from similar drugs shed light on potential pricing behaviors:
- Brand-Name Biologics: These carry list prices often exceeding $5,000-$15,000 per treatment cycle (e.g., for monoclonal antibodies).
- Biosimilars and Generics: These typically see reductions of 20-40% compared to originators upon market entry.
- Pricing Erosion: Historically, biologic prices tend to decrease gradually due to increased competition and biosimilar market entries.
Notably, the FDA's biosimilar pipeline and approval data impact future price projections, especially if NDC 83324-0155 pertains to a biologic.
Market Entry and Competition Outlook
Anticipated biosimilar entries or new therapeutics can reshape the competitive landscape:
- Biosimilar Impact: The entry of biosimilars in the US has historically driven prices down by approximately 15-30%, with the most significant impact observed within 2-3 years of biosimilar approvals.
- Regulatory Changes: Policy shifts aimed at promoting biosimilars may further accelerate price reductions.
- Global Pricing Trends: International reference pricing influences US market prices through importation and pricing benchmarks.
Pricing Projections
Based on historical data, market dynamics, and regulatory outlooks, the following projections are reasonable:
Short-term (1-2 years):
- Price stabilization at current levels or slight reductions (5-10%) due to increased payer negotiations and market penetration.
Medium-term (3-5 years):
- Price erosion expected to accelerate, particularly if biosimilars or alternative therapies gain approval and market share, with potential price declines of 20-40%.
Long-term (5+ years):
- Continued downward pressure, possibly leading to substantial genericized pricing or redefined value-based pricing models, especially if patent exclusivity ends.
Factors Enhancing Price Declines:
- Patent expiry timelines
- Biosimilar approval and uptake rates
- Competitive entry from alternative therapies
- Policy interventions and payer strategies
Economic Impact and Stakeholder Considerations
For Manufacturers:
Strategic investments in lifecycle management, biosimilar development, or indication expansions are critical to sustain profitability amid pricing pressures.
For Payers and Policymakers:
Implementing cost-containment policies, promoting biosimilar utilization, and negotiating formulary placements influence market prices profoundly.
For Healthcare Providers and Patients:
Price fluctuations affect affordability and access, emphasizing the need for transparent pricing models and value-based care frameworks.
Conclusion
NDC 83324-0155 exists within a complex ecosystem shaped by patent protections, competition, regulatory environments, and healthcare policy trends. Price projections must incorporate these dynamics, with short-term stability giving way to gradual declines owing to biosimilar competition and increased market maturity. Organizations should monitor regulatory updates, biosimilar pipelines, and payer policies to refine pricing strategies and maximize market positioning.
Key Takeaways
- The pricing of NDC 83324-0155 is likely to remain stable in the immediate term but declines in the medium to long term due to biosimilar competition and patent expirations.
- A strategic focus on lifecycle management and indication expansion can help sustain profitability.
- Biosimilar and alternative therapy approvals are critical indicators for future price trajectories.
- Policymakers' push for biosimilar adoption and reimbursement strategies directly influence market prices.
- Continuous monitoring of regulatory and competitive developments is necessary for accurate forecasting and strategic planning.
FAQs
1. What is the typical timeframe for biosimilar entry impacting the pricing of biologic drugs?
Biosimilar approvals usually occur 8-12 years after the original biologic's market entry. The impact on pricing generally manifests within 2-3 years post-approval as biosimilars gain market share.
2. How do patent expirations affect the pricing of NDC 83324-0155?
Patent expirations open the market for biosimilars or generics, leading to increased competition and significant price reductions—often 20-40%.
3. Can manufacturers maintain premium pricing even after patent expiration?
Yes, through indication-specific patents, manufacturing exclusivities, or value-added therapies, some manufacturers can sustain higher prices longer.
4. What role do healthcare payers play in influencing the pricing of this drug?
Payers negotiate reimbursement rates, promote biosimilar use, and implement formulary restrictions to control costs, thereby impacting the drug’s market price.
5. How can stakeholders prepare for future price changes of NDC 83324-0155?
By monitoring regulatory approvals, competitor entries, and policy trends; investing in lifecycle management; and engaging in value-based pricing negotiations.
Sources:
[1] U.S. Food and Drug Administration (FDA) NDC Directory
[2] EvaluatePharma: Biologic and Biosimilar Pricing Trends
[3] ASMR International Reports on Biosimilar Market Penetration
[4] McKinsey & Company: Biosimilars Impact on Market Prices
[5] Centers for Medicare & Medicaid Services (CMS) Policy Updates
More… ↓
